Parametric Portfolio Associates LLC increased its holdings in AstraZeneca plc (NYSE:AZN) by 11.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,790,092 shares of the company’s stock after buying an additional 186,457 shares during the period. Parametric Portfolio Associates LLC owned about 0.07% of AstraZeneca worth $60,648,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. SG Americas Securities LLC lifted its position in AstraZeneca by 29.8% in the 2nd quarter. SG Americas Securities LLC now owns 25,919 shares of the company’s stock valued at $884,000 after purchasing an additional 5,956 shares during the last quarter. Bank of New York Mellon Corp lifted its position in AstraZeneca by 6.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 195,965 shares of the company’s stock valued at $6,681,000 after purchasing an additional 11,311 shares during the last quarter. Opus Capital Group LLC bought a new stake in AstraZeneca in the 2nd quarter valued at about $202,000. Blair William & Co. IL lifted its position in AstraZeneca by 62.3% in the 2nd quarter. Blair William & Co. IL now owns 42,117 shares of the company’s stock valued at $1,436,000 after purchasing an additional 16,174 shares during the last quarter. Finally, Marshall Wace North America L.P. bought a new stake in AstraZeneca in the 2nd quarter valued at about $11,007,000. 14.75% of the stock is owned by institutional investors and hedge funds.
AZN has been the topic of a number of recent analyst reports. Argus restated a “buy” rating and set a $35.00 price target on shares of AstraZeneca in a research report on Friday, September 1st. Natixis upgraded shares of AstraZeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, September 6th. BMO Capital Markets initiated coverage on shares of AstraZeneca in a research report on Wednesday, September 6th. They set an “outperform” rating and a $38.00 price target on the stock. Liberum Capital downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, September 14th. Finally, Sanford C. Bernstein upgraded shares of AstraZeneca from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $30.00 to $39.00 in a research report on Friday, September 22nd. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $34.20.
AstraZeneca (NYSE:AZN) last announced its quarterly earnings data on Thursday, November 9th. The company reported $1.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.57 by $0.55. The company had revenue of $6.23 billion for the quarter, compared to analysts’ expectations of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The business’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.32 EPS. sell-side analysts anticipate that AstraZeneca plc will post 1.87 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Parametric Portfolio Associates LLC Boosts Stake in AstraZeneca plc (AZN)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.com-unik.info/2017/12/19/parametric-portfolio-associates-llc-boosts-stake-in-astrazeneca-plc-azn.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
What are top analysts saying about AstraZeneca? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AstraZeneca and related companies.